Results With Rituxan
Rituxan® (rituximab), in combination with glucocorticoids, is the only FDA-approved induction therapy for adults with Granulomatosis with Polyangiitis (GPA) and Microscopic Polyangiitis (MPA). Talk with your doctor to see if Rituxan may be right for you.
Rituxan, in combination with glucocorticoids, may help put GPA and MPA into complete remission*
The Rituximab in ANCA-Associated Vasculitis (RAVE) trial was conducted by the National Institute of Allergy and Infectious Diseases and the Immune Tolerance Network with support from Genentech and Biogen. The goal of the trial was to see if Rituxan in combination with glucocorticoids worked as well as cyclophosphamide (control group) in bringing on complete remission at 6 months in adults with GPA and MPA.
The RAVE Trial showed that Rituxan worked as well as cyclophosphamide (64% vs 53%, respectively) to achieve complete remission at 6 months. Also in the study, there was no significant difference in the rates of remission at 6, 12, or 18 months for patients treated with Rituxan compared with patients who received CYC followed by AZA (38% for Rituxan group and 31% for the control group). The study also showed that there were no major differences between the overall side effects experienced by each group.
*In a clinical trial for Rituxan, "complete remission" was defined as no disease activity and being able to stop steroids.
What is the most important information I should know about Rituxan?
Rituxan can cause serious side effects that can lead to death, including:
- Infusion Reactions: Infusion reactions are the most common side effect of Rituxan treatment. Serious infusion reactions can happen during your infusion or within 24 hours after your infusion
- Severe Skin and Mouth Reactions: Tell your healthcare provider if you get any of these symptoms during treatment with Rituxan: painful sores or ulcers on your skin, lips, or in your mouth; blisters; peeling skin; rash; or pustules
- Hepatitis B Virus (HBV) Reactivation: If you have had hepatitis B or are a carrier of hepatitis B virus, receiving Rituxan could cause the virus to become an active infection again. Hepatitis B reactivation may cause serious liver problems, including liver failure and death. You should not receive Rituxan if you have active hepatitis B liver disease
- Progressive Multifocal Leukoencephalopathy (PML): PML is a rare, serious brain infection caused by a virus that can happen in people who receive Rituxan. People with weakened immune systems can get PML. PML can result in death or severe disability. There is no known treatment, prevention, or cure for PML
Please see below and the Rituxan Medication Guide for additional Important Side Effect Information, including Most Serious Side Effects.